Artelo Biosciences ARTL

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics that target lipid signaling modulation pathways including the endocannabinoid system. The company was incorporated in the State of Nevada on May 2 2011 and maintains its principal executive offices in Solana Beach California. Its core activities involve advancing three distinct product candidates through preclinical and clinical stages. The lead candidate ART27.13 is a synthetic dual cannabinoid receptor agonist being evaluated for cancer related anorexia. A second candidate ART26.12 is a small molecule inhibitor of fatty acid binding protein five being studied for chemotherapy induced peripheral neuropathy and other indications. The third candidate ART12.11 is a proprietary cocrystal of cannabidiol and tetramethylpyrazine aimed at anxiety and related disorders. These programs are supported by patented compositions and exclusive licensing agreements with academic and corporate partners.

Artelo Biosciences, Inc. has not yet received marketing approval for any of its product candidates and therefore does not generate product sales revenue. The company funds its research and development activities through proceeds from public and private equity offerings. The proceeds from equity offerings are allocated to cover IND enabling studies manufacturing scale up and general and administrative expenses. Additionally it has entered into licensing arrangements that may provide milestone payments and royalties upon successful development and commercialization of licensed compounds. Grant awards from government and nonprofit institutions also contribute to its operating budget. Until a product reaches the market the company’s revenue consists primarily of these financing and collaboration related inflows.

Artelo Biosciences, Inc. operates in the highly competitive biopharmaceutical sector where numerous large and small companies pursue therapies targeting the endocannabinoid system and lipid signaling pathways. Its direct competitors include established pharmaceutical firms such as Novartis International AG, Helsinn Therapeutics Inc., NGM Biopharmaceuticals Inc., Jazz Pharmaceuticals Inc., Skye Bioscience, Longboard Pharmaceuticals and Pfizer Inc. These competitors possess greater financial resources broader research and development infrastructures and more extensive commercialization experience. Artelo differentiates itself by concentrating on novel chemical entities that modulate lipid signaling through mechanisms distinct from traditional cannabinoid based approaches. The company’s exclusive licenses for ART27.13 and ART26.12 provide access to chemically validated compounds with favorable preclinical profiles. Its proprietary cocrystal technology for ART12.11 aims to improve the pharmacokinetic properties of cannabidiol offering a potential advantage over existing cannabidiol formulations. Strong patent protection covering composition of matter and methods of use further supports its competitive stance.

Artelo Biosciences, Inc. does not currently serve paying customers because its product candidates remain under investigation. The intended recipients of its therapies are patients suffering from specific medical conditions such as cancer related anorexia chemotherapy induced peripheral neuropathy and anxiety disorders. Healthcare providers including oncologists neurologists and primary care physicians would prescribe the treatments upon regulatory approval. Hospitals clinics and specialty treatment centers are expected to be the settings where the drugs are administered. The company also anticipates forming partnerships with patient advocacy groups and research networks to support clinical trial enrollment and post market surveillance. The company expects that positive clinical outcomes will lead to prescription demand from specialists treating the targeted conditions.